These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 33893689)

  • 21. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study).
    Yang Y; Zhu L; Cheng Y; Liu Z; Cai X; Shao J; Zhang M; Liu J; Sun Y; Li Y; Yi J; Yu B; Jiang H; Chen H; Yang H; Tan L; Li Z
    BMC Cancer; 2022 May; 22(1):506. PubMed ID: 35524205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
    Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
    Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
    BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant camrelizumab followed by concurrent camrelizumab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, phase II study.
    Sheng Y; Meng X; Zhang C; Shan Z; Li F; Wu B; Xu M; Li A; Guan L; Chen L; Sun S; Ma Y; Lu T; Zhao S; Fan Q; Qi Y; Wang F
    J Thorac Dis; 2024 Aug; 16(8):5337-5347. PubMed ID: 39268120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Camrelizumab combined with apatinib for unresectable, metastatic esophageal squamous cell carcinoma: a single-center, single-arm, prospective study.
    Qu Y; Munire A; Zhou N; Saifuding K; Bulibu J; Wang W; Tang X; Li N; Li J; Wang P; Tang Y
    J Gastrointest Oncol; 2024 Feb; 15(1):1-11. PubMed ID: 38482217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.
    Yan C; Ma X; Guo Z; Wei X; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao G; Gao X; Wang T; Jiang Y; Wang P; Pang Q; Zhang W
    Oncoimmunology; 2022; 11(1):2025668. PubMed ID: 35036077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and toxicity of anlotinib plus camrelizumab versus anlotinib plus S-1 as second-line therapy for advanced esophageal squamous cell carcinoma: A real-world retrospective study.
    Zhang W; Chen M; Dai H; Sun W
    Cancer Pathog Ther; 2024 Oct; 2(4):276-284. PubMed ID: 39371099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Park S; Oh D; Choi YL; Chi SA; Kim K; Ahn MJ; Sun JM
    Cancer; 2022 Jun; 128(11):2148-2158. PubMed ID: 35319779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma.
    Chen F; Qiu L; Mu Y; Sun S; Yuan Y; Shang P; Ji B; Wang Q
    Front Surg; 2022; 9():893372. PubMed ID: 35983558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.
    Chen YY; Wang PP; Hu Y; Yuan Y; Yang YS; Shi HS; Hao Q; Lin Z; Tian JF; Zheng Y; Liu T; Lin PP; Xu H; Ma XL; Yang L; Ding ZY
    Br J Cancer; 2024 Oct; 131(7):1126-1136. PubMed ID: 39164491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial.
    Jiang N; Zhang J; Guo Z; Wu Y; Zhao L; Kong C; Song X; Gu L; Zhao Y; Li S; He X; Ren B; Zhu X; Jiang M
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38199609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
    Liu J; Yang Y; Liu Z; Fu X; Cai X; Li H; Zhu L; Shen Y; Zhang H; Sun Y; Chen H; Yu B; Zhang R; Shao J; Zhang M; Li Z
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
    Liu J; Zhu L; Huang X; Lu Z; Wang Y; Yang Y; Ye J; Gu C; Lv W; Zhang C; Hu J
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):161. PubMed ID: 38536527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
    He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
    Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous carcinoma cancer: Results from a retrospective study.
    Kang NN; Zheng H; Hu JX; Cui K; Si PP; Ge W
    Kaohsiung J Med Sci; 2024 Mar; 40(3):291-295. PubMed ID: 38088519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
    Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
    Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study.
    Zhou RQ; Luo J; Li LJ; Du M; Wu QC
    BMC Surg; 2023 May; 23(1):114. PubMed ID: 37161374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of dynamic changes in the peripheral CD8
    Wei H; Li Y; Guo Z; Ma X; Li Y; Wei X; Han D; Zhang T; Chen X; Yan C; Zhou J; Pang Q; Wang P; Zhang W
    Front Immunol; 2022; 13():1060695. PubMed ID: 36479110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world.
    Wang HC; Huang X; Chen J; Li Y; Cong Y; Qu BL; Feng SQ; Liu F
    World J Gastroenterol; 2023 Nov; 29(41):5641-5656. PubMed ID: 38077159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.
    Chen B; Li Q; Li Q; Qiu B; Xi M; Liu M; Hu Y; Zhu Y
    Oncologist; 2020 Apr; 25(4):308-e625. PubMed ID: 31880371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.